Heron Therapeutics v. Mylan: 10-Patent Aprepitant Emulsion Dispute Consolidated in Delaware
Heron Therapeutics filed suit against Mylan in the District of Delaware asserting 10 patents covering emulsion formulations and methods of use of the NK-1 receptor antagonist aprepitant. After 585 days, the case was consolidated with a related action — C.A. No. 23-1015 — covering the same patent portfolio, concentrating all proceedings before Judge William C. Bryson.
A ten-patent emulsion portfolio triggers Delaware consolidation
On January 11, 2024, Heron Therapeutics, Inc. filed suit in the District of Delaware (Case No. 1:24-cv-00043) against Mylan, NV, asserting infringement of ten United States patents covering emulsion formulations of aprepitant — an NK-1 receptor antagonist — and the methods of use of those formulations. The asserted patents span a broad portfolio addressing composition, formulation, and therapeutic-use claims for Heron’s proprietary intravenous emulsion product.
The case was terminated on August 18, 2025, not on the merits but through a court-approved consolidation order. The parties stipulated, and the court agreed, that C.A. No. 24-43 concerns the same patents and the same parties as the earlier-filed C.A. No. 23-1015, also pending before Judge Bryson. Under the consolidation, all filings and scheduling deadlines now operate under the lead case docket, effectively absorbing this action into the broader proceedings.
The 585-day duration before consolidation suggests the parties were managing parallel ANDA-related litigation tracks, a pattern consistent with pharmaceutical patent disputes where brand holders file successive suits as generic applicants submit additional certifications. The public record for this docket is now silent on substantive merits, claim construction, and any licensing posture — all of which will surface, if at all, in C.A. No. 23-1015.
Filing to Case Consolidated in 585 days
585 days — above average for a Delaware ANDA consolidation order
Case consolidated: what the merger into C.A. No. 23-1015 means for both parties
Consolidation absorbs this case into an earlier-filed action
A consolidation order under Federal Rule of Civil Procedure 42(a) merges related actions that share common questions of law or fact. Here, both C.A. No. 23-1015 and C.A. No. 24-43 involve the same patents, same parties, and the same product. The lead case (23-1015) controls all filings and deadlines going forward. This docket is effectively dormant — not dismissed, not decided.
Procedural — no merits rulingHeron’s full patent portfolio remains live in the lead case
For Heron Therapeutics, consolidation is procedurally neutral to positive. All ten patents asserted here carry forward into C.A. No. 23-1015, preserving Heron’s full enforcement posture. Consolidation avoids duplicative proceedings and reduces the risk of inconsistent rulings on claim construction — a meaningful advantage when managing a ten-patent portfolio against a single generic challenger.
Patent rights preservedMylan faces consolidated multi-patent challenge in a single proceeding
For Mylan, consolidation concentrates risk: all patent claims from both dockets must now be defended simultaneously in C.A. No. 23-1015. This eliminates the prospect of a favourable ruling in one case offsetting the other. However, it also streamlines discovery and claim construction briefing, which typically benefits the better-resourced party in complex pharmaceutical litigation.
Combined exposure in lead caseAprepitant generic entry timeline remains uncertain pending lead case outcome
Until C.A. No. 23-1015 reaches a final decision, Mylan’s ability to launch a generic aprepitant emulsion product in the US market is subject to the 30-month stay typically triggered by Hatch-Waxman ANDA litigation. The consolidation suggests this dispute has escalated in scope — ten patents in play signals Heron intends to defend its emulsion franchise aggressively, which typically extends uncertainty for generic entry timelines.
Generic entry: stay likely activeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Heron Therapeutics, Inc. | Company | Pharmaceutical company — holder of US10624850B2 and 9 related aprepitant emulsion patentsSearch in Eureka ↗ |
| Defendant | Mylan, NV | Company | Global generic pharmaceutical manufacturer — Mylan, NV, alleged ANDA filer for aprepitant emulsionSearch in Eureka ↗ |
| Plaintiff counsel | Anthony David Raucci | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Bruce M. Wexler | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher P. Hill | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Isaac S. Ashkenazi | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark Russell Sperling | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Heron Therapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | David E. Moore | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Potter, Anderson & Corroon LLP | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation stipulation is procedural in nature and carries no substantive finding on infringement, validity, or damages. The court’s approval confirms that both dockets involve the same patents and parties — a factual predicate, not a merits ruling. The operative legal proceedings now sit entirely within C.A. No. 23-1015, and any claim construction, summary judgment, or trial outcome in that case will govern the rights of both parties with respect to all ten patents asserted here.
US10624850B2 — Aprepitant NK-1 receptor antagonist emulsion formulations
The ten asserted patents collectively protect Heron Therapeutics’ proprietary approach to formulating aprepitant — an NK-1 receptor antagonist used clinically to prevent chemotherapy-induced nausea and vomiting — as an intravenous emulsion. The portfolio spans composition claims (covering the emulsion structure itself), formulation claims (covering specific ingredient ratios and preparation methods), and method-of-use claims (covering therapeutic administration protocols). Application priority dates range across filings from US14/859013 through US17/979577, suggesting a sustained prosecution strategy building successive layers of protection around a core emulsion technology.
Strategically, this portfolio is designed to create overlapping protection that is difficult to design around. Any generic manufacturer seeking to market an intravenous aprepitant emulsion must contend with claims covering not just the composition but also the therapeutic method — meaning even a reformulated product could infringe method-of-use claims if administered in the same clinical context. For competitors and licensing teams, the breadth of this portfolio makes freedom-to-operate analysis non-trivial and elevates the value of early IPR or inter partes review challenges before any ANDA is approved.
Should you run an FTO against Heron’s aprepitant emulsion patent portfolio?
Any company developing, manufacturing, or seeking to commercialise an intravenous NK-1 receptor antagonist emulsion — particularly aprepitant-based products — in the US market should treat this ten-patent portfolio as a high-priority FTO target. The combination of composition, formulation, and method-of-use patents means that product-level clearance alone is insufficient; clinical use protocols and administration routes must also be assessed against the method claims. ANDA filers in particular face mandatory engagement with this portfolio under Hatch-Waxman.
PatSnap Eureka’s FTO Search Agent can map each of the ten asserted patents against your product specifications, flag overlapping claim language, and identify prosecution history estoppel that may limit claim scope. Eureka’s citation analysis also surfaces the closest prior art for IPR petitions — critical intelligence if you are evaluating a challenge strategy in parallel with ANDA prosecution. For a portfolio of this size and depth, automated claim-by-claim mapping is significantly faster than manual review.
Run a freedom-to-operate analysis on US10624850B2 to assess your product’s exposure
Run FTO in Eureka →Similar NK-1 receptor antagonist emulsion patent cases in Delaware
Explore related Hatch-Waxman pharmaceutical emulsion patent disputes before the Delaware District Court involving NK-1 antagonist and parenteral formulation IP.
What this case signals for the pharmaceutical emulsion IP landscape
A ten-patent consolidation in Delaware’s busiest pharma court signals an escalating formulation IP battle with real consequences for generic market access.
Multi-patent ANDA strategies create compounding litigation risk for generics
Heron’s deployment of ten patents across formulation, composition, and method-of-use claims is a textbook patent thicket strategy. For generic challengers, each additional patent extends the litigation runway and raises the cost of a successful market entry. R&D teams developing alternative NK-1 emulsion formulations should map the full Heron portfolio — not just the lead patent — before filing.
Consolidation signals coordinated enforcement, not weakness
When a brand holder agrees to consolidation, it typically signals confidence that the combined case strengthens rather than dilutes its position. Heron’s willingness to merge both dockets under one judge suggests a unified litigation strategy. In-house teams tracking this space should monitor C.A. No. 23-1015 closely — it will be the definitive venue for claim construction rulings on this emulsion portfolio.
Heron v Mylan — key questions answered
Case No. 1:24-cv-00043 was consolidated with the related action C.A. No. 23-1015 (WCB) before Judge William C. Bryson in the Delaware District Court. The case involved the same ten patents and the same parties as the earlier-filed action. All proceedings, filings, and scheduling deadlines are now governed by the lead case C.A. No. 23-1015. No merits ruling was issued in this docket.
Heron asserted ten US patents: US10624850B2, US10953018B2, US11744800B2, US9974793B2, US9974794B2, US11173118B2, US10500208B2, US9808465B2, US9561229B2, and US9974742B2. The patents collectively cover emulsion formulations of aprepitant, an NK-1 receptor antagonist, including composition, formulation, and method-of-use claims for parenteral administration.
Consolidation under FRCP 42(a) merges related actions sharing common legal or factual questions. In Hatch-Waxman litigation, brand holders sometimes file successive suits as new ANDA certifications are received. Consolidation prevents duplicative proceedings and inconsistent rulings, particularly on claim construction. The merged case proceeds under the lead docket, and the absorbed case is administratively closed without a merits finding.
The public record does not confirm the specific regulatory status of Mylan’s ANDA or whether a 30-month stay is currently operative. However, the filing of this patent infringement action is consistent with Hatch-Waxman practice, under which a timely-filed infringement suit typically triggers a 30-month stay of FDA approval. The stay status would be governed by the lead case C.A. No. 23-1015.
Heron Therapeutics is represented by Morris, Nichols, Arsht & Tunnell LLP, with a team including Jack B. Blumenfeld and Jeremy A. Tigan, alongside Paul Hastings LLP attorneys including Bruce M. Wexler. Mylan is represented by Potter, Anderson & Corroon LLP, with David E. Moore listed as lead counsel in this docket. Both are prominent Delaware patent litigation firms.
PatSnap Eureka searches patents and litigation data to answer instantly.